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c-Jun N-terminal kinases (JNKs) are a family of protein kinases that play a central
role in stress signaling pathways implicated in gene expression, neuronal plasticity,
regeneration, cell death, and regulation of cellular senescence. It has been shown that
there is a JNK pathway activation after exposure to different stressing factors, including
cytokines, growth factors, oxidative stress, unfolded protein response signals or Aβ
peptides. Altogether, JNKs have become a focus of screening strategies searching
for new therapeutic approaches to diabetes, cancer or liver diseases. In addition,
activation of JNK has been identified as a key element responsible for the regulation
of apoptosis signals and therefore, it is critical for pathological cell death associated
with neurodegenerative diseases and, among them, with Alzheimer’s disease (AD).
In addition, in vitro and in vivo studies have reported alterations of JNK pathways
potentially associated with pathogenesis and neuronal death in AD. JNK’s, particularly
JNK3, not only enhance Aβ production, moreover it plays a key role in the maturation
and development of neurofibrillary tangles. This review aims to explain the rationale
behind testing therapies based on inhibition of JNK signaling for AD in terms of current
knowledge about the pathophysiology of the disease. Keeping in mind that JNK3 is
specifically expressed in the brain and activated by stress-stimuli, it is possible to
hypothesize that inhibition of JNK3 might be considered as a potential target for treating
neurodegenerative mechanisms associated with AD.
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INTRODUCTION
Since its discovery more than 20 years ago, the c-Jun N-terminal kinase family (JNK) has remained
a subject of intense research interest with continued eﬀorts to evaluate its biochemistry and
regulation, and its contribution to cellular events under physiological and pathophysiological
conditions. The JNK family of protein kinases is one of the three identiﬁed families of mitogen
activated protein (MAP) kinases. Three genes, namely jnk1 (MAPK8), jnk2 (MAPK9), and jnk3
(MAPK10), encode for 10 diﬀerent splice variants with molecular weights of 46 and 55 kDa (Davis,
2000). Whereas, JNK1 and JNK2 have a broad tissue distribution, JNK3 is mainly localized in
neurons and to a lesser extent in the heart and the testis.
The discovery of JNK pathway scaﬀolds such as JNK-interacting protein-1 (JIP1) and related
proteins, as well as the identiﬁcation of JNK inhibitors have contributed to unmask the roles for the
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JNKs in both normal physiology and disease. JNK signaling
process has been studied as an active pathological mechanism
in many diﬀerent diseases, especially in the ﬁeld of oncology. To
mention a few, JNK has been involved in regulation of the natural
killer cells’ cytokine production and secretion (Lee et al., 2014),
oncology models and drug-resistant tumor cells (Chuang et al.,
2014; Kim et al., 2014; Okada et al., 2014; Volk et al., 2014) or
myeloproliferative disorders (Funakoshi-Tago et al., 2012).
Transgenic knockouts of JNK isoforms have provided crucial
insights into the roles played in the brain by each JNK isoform.
It has been established that JNK1 and JNK2 have important
roles in the modulation of immune cell function and in the
development of the embryonic nervous system. A study using
JNK1 knockout mice demonstrated that JNK1 has a regulatory
role and maintains physiological functions in the CNS, while
JNK2 knockout established that this isoform may also participate
in some physiological functions and, particularly, in the long term
potentiation (LTP; Chen et al., 2005). JNK3 is a multifunctional
enzyme important in controlling brain functions under both
normal and pathological conditions. JNK3 has been implicated
in brain development (Kuan et al., 1999), neurite formation and
plasticity (Waetzig et al., 2006; Eminel et al., 2008), in addition to
memory and learning (Bevilaqua et al., 2003; Brecht et al., 2005).
Under pathological conditions, JNK3 has been considered as a
degenerative signal transducer and it seems to be the isoform
involved in over-activation of JNK after deleterious stress-stimuli
in adult brain (ischemia, hypoxia, epilepsies). This principle is
supported by the data on the reduced apoptosis of hippocampal
neurons and reduced seizures induced by kainic acid in JNK3
knockout (–/–) mice, and by the notion that JNK3–/– mice
are also protected against ischemia (Yang et al., 1997; Okazawa
and Estus, 2002; Sahara et al., 2008). Therefore, there is now
considerable interest in further studying the involvement of this
isoform in the development of neurodegenerative disease, such as
Alzheimer’s disease (AD).
JNK SIGNALING
Activation of the JNK pathway relies on the coordinated
interaction of the scaﬀold proteins belonging to the JNK
activation complex. These proteins are able to mediate the
biochemical signal ampliﬁcation and also to ensure substrate-
speciﬁcity as well as a coordinated cascade signaling (Figure 1).
The interaction between scaﬀold proteins leads to the activation
of JNK by bi-phosphorylating diﬀerent substrates, enables the
activation of diﬀerent functions (Antoniou et al., 2011).
Diﬀerent stimuli that have been described as able to trigger
the signaling response to JNK include nerve growth factor (NGF)
deprivation, trophic support withdrawal, DNA damage, oxidative
stress, βamyloid (Aβ) exposure, low potassium, excitotoxic stress,
6-OHDA, UV irradiation, tumor necrosis factor (TNF), or the
Wnt cascade Mudher et al., 2001; Cui et al., 2007). Many are
the scaﬀold proteins that have been described as the signaling
proteins that converge in the activation of JNK: JIP1a (JNK
interacting protein 1a) and JIP1b (also named IB1), JIP2 and JIP3
(ﬁrstly named JSAP1) JNK-interacting leucine zipper protein
(JLP) and plenty of SH3 (POSH; Engstrom et al., 2010). JIPs
belong to second-order-activating proteins that are dependent on
previous interaction with MAPK activating kinases (MAPKKs)
and MAPKK activating kinases (MAPKKKs; Wang et al., 2004;
Cui et al., 2007; Engstrom et al., 2010; Figure 1). Thus, the
coordination of what is called the “signalosome” that leads to
the activation of JNK is complex and requires interaction of ﬁrst
messengers at diﬀerent cellular levels for further activation of the
scaﬀold-protein-complex and ﬁnally activating JNK.
Endoplasmic reticulum’s (ER) stress phenomena that induce
the unfolded protein response (UPR) signaling are also involved
in the control of activation of JNK pathway (Figure 1). As a result
of anomalous protein burden, an interaction between Ire1 (ER to
nucleus signaling 1) and Presenilin 1 (PS1) has been proposed
to enable the activation of JNK thus leading to proapoptotic
signaling activation (Shoji et al., 2000). Direct modulation of
JNK-activation by the cdk5/p35 complex has also been described,
although the underlying mechanisms that lead to this molecular
phenomenon are still unclear (Otth et al., 2003).
The main cellular substrate activated by JNK mediated
phosphorylation is c-Jun (Figure 2), which in turn is able to
interact with JunB, JunD, c-Fos, and ATF constituting the AP-
1 transcription factor (Pearson et al., 2006; Cui et al., 2007)
and, thus, regulating maturation of the cellular stress-response or
modulating the signals that lead ﬁnally to activation of caspases
(Nishina et al., 2004; Pearson et al., 2006). Moreover, JNK is able
to phosphorylate and activate directly apoptosis-related proteins
such as BIM (homologous to BAX) and BMF (Okazawa and
Estus, 2002; Cui et al., 2007), both proapoptotic proteins resulting
in activation of caspases. JNK also phosphorylates DP5-HRK,
Bcl-2, and Bcl-xL (Okazawa and Estus, 2002; Cui et al., 2007),
which are anti-apoptotic proteins inhibited by phosphorylation
by JNK (Figure 2).
Furthermore, it has also been described that JNK might exert
its eﬀects via microRNA (miRNA) mechanisms or regulation of
histone H3 acetylation, as reviewed by Bogoyevitch et al. (2010).
JNK AND ALZHEIMER’S DISEASE
Alzheimer disease is an age-related neurodegenerative disorder
clinically characterized by progressive deterioration of cognitive
functions. At cellular level, major neuropathological lesions
of AD include extracellular deposits of Aβ peptides leading
to formation of senile/neuritic plaques and intracellular
neuroﬁbrillary tangles (NFTs) which are paired helical ﬁlaments
(PHFs) of hyper-phosphorylated tau proteins (Haas, 2012).
It has been shown an increased expression of phosphorylated
JNK (pJNK) in human post-mortem brain samples from AD
patients and a positive co-localization with Aβ (Zhu et al., 2001;
Killick et al., 2014). In particular, JNK3 is highly expressed and
activated in brain tissue and cerebrospinal ﬂuid from patients
with AD and statistically correlated with the rate of cognitive
decline (Gourmaud et al., 2015). In fact, it has been described
that Aβ peptides are able to induce JNK activation, as it has
been found in vitro that p JNK increases after treatment with
Aβ in primary cortical and hippocampal cultures from C57BL/6
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FIGURE 1 | Simplified diagram showing mechanisms involved in activation of the JNK pathway. Different stress conditions might activate JNK signaling via
scaffold proteins. UPR and an interaction between Ire1 and PS1 have also been described as potential activators of JNK. ROS, radical oxygen species; Aβ,
βamyloid; JIP, JNK interacting protein; UPR, unfolded protein response; Ire, endoplasmic reticulum to nucleus signaling 1.
mice, in primary cortical cell cultures from Wistar rat and in
SH-SY5Y neuroblastoma cells (Morishima et al., 2001; Suwanna
et al., 2014; Xu et al., 2015). Interestingly, Yoon et al. (2012)
demonstrated that JNK3 is the major kinase for β-amyloid
precursor protein (APP) phosphorylation at T668 (Figure 2). In
fact, genetic depletion of JNK3 in transgenic AD mice resulted
in a dramatic reduction in Aβ42 peptide levels and overall
plaque loads as well as in an increased number of neurons and
improved cognition (Yoon et al., 2012). Some reports conﬁrmed
that JNK3-mediated phosphorylation regulated APP cleavage by
inducing the amyloidogenic processing of the protein, while JNK
inhibition reduced amyloidogenic processing in favor of the non-
amyloidogenic route in vitro by blocking APP phosphorylation
(Morishima et al., 2001; Savage et al., 2002; Colombo et al., 2009).
In experimental models of AD, research using a mouse model
of AD that incorporates the Swedish APPmutation and a mutant
presenilin-1 (PS1) -Tg2576/PS1- has demonstrated that JNK
activation is associated with increased levels of senile plaques
and NFT’s (Savage et al., 2002). However, in contrast with these
data, no signiﬁcant diﬀerences were found in pJNK levels in the
triple transgenic mice (3xTg mice; Feld et al., 2014). Research
has also been conducted in experimental models of AD based
on well-known risk factors contributing to the development of
AD, such as stress or insulin resistance (Dhikav and Anand,
2007). In mice subjected to chronic mild stress (CMS) known
to increase tau misprocessing and amyloidogenic processing,
JNK phosphorylation is increased (Solas et al., 2013a). The
intracerebroventricular administration of subdiabetogenic doses
of streptozotocin (STZ) induced cognitive and brain cholinergic
deﬁcits, oxidative stress, insulin resistant brain state and high
levels of pJNK (Giuliani et al., 2013; Martisova et al., 2013;
Salkovic-Petrisic et al., 2013; Solas et al., 2013b; Xiong et al.,
2013). It is to be noted that JNK may also directly induce insulin
resistance, as JNK phosphorylates insulin receptor substrate (IRS)
1 blocking the transduction signal produced by the insulin
receptor (Sabio et al., 2008).
The etiology of AD remains elusive, but the nosogenic basis of
AD seems to be related to neuron apoptosis and loss of synaptic
terminals within the central nervous system’s parenchyma. Thus,
the increased concentration of reactive oxygen intermediates
(ROIs) and superoxide dismutase, both markers of cellular
stress, and increased intracellular calcium in AD are congruent
with an underlying activation of apoptotic mechanisms via
mitochondrial dysfunction. However, the molecular mechanisms
that lead to the activation of apoptotic signals are not fully
understood. There is evidence that Aβ42 induces a translational
block leading to activation of JNK (Yoon et al., 2012), which
in turn, results in neuroinﬂammation and neurodegeneration.
It has been suggested that neurodegeneration in early age of
AD patients could be a result of an increased vulnerability of
neurons through activation of diﬀerent apoptotic pathways as a
consequence of elevated levels of oxidative stress, and that these
eﬀects could be mediated by JNK activation (Marques et al., 2003;
Sahara et al., 2008). Furthermore, JNKs were involved in Aβ
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FIGURE 2 | Cellular mechanisms activated by JNK phosphorylation. Activated JNK leads to phosphorylation of c-Jun, which modulates gene expression as
well as tangle maturation. JNK plays also a direct role in the formation of tangles by phosphorylation of Tau and it also contributes to the regulation of PHF formation
and proteolytic cleavage processing. Finally, JNK is responsible for the phosphorylation of BIM and BMF and, as consequence, for the activation of caspases leading
to cellular apoptosis.
triggered down regulation of the anti-apoptotic Bcl-w (Yao et al.,
2005) and activation of Toll-like receptor 4 (TLR4) signaling
(Figure 2). Neurons from TLR4 mutant mice exhibit reduced
JNK and caspase-3 activation and protect against Aβ induced
apoptosis (Tang et al., 2008).
c-Jun has been identiﬁed to play other possible roles in
AD, e.g., phosphorylated c-Jun burdens within the structure of
NFTs may play an indirect regulatory role in tangle maturation
in AD, mostly regulated by its phosphorylation by JNK. Due
to the imbalance established between decreased PP2A (protein
phosphatase 2) expression and JNK mediated phosphorylation
of c-Jun, phospho-c-Jun are preponderant over the non-
phosphorylated form. As a matter of fact, phospho-c-Jun shows
a lesser tendency for its degradation via proteasomes, leading to
its accumulation within NFTs and, thus, contributing to tangle
maturation process (Pearson et al., 2006; Figure 2).
c-Jun N-terminal kinase also modulates directly the formation
of NFTs (Figure 2) by direct phosphorylation of Tau (Lagalwar
et al., 2006). In vitro phosphorylation experiments show
that the JNK3 isoform can strongly autophosphorylate
itself and contribute to Tau hyperphosphorylation (Vogel
et al., 2009). JNK was identiﬁed to phosphorylate Tau at
Ser422, and concretely, JNK3 has the highest aﬃnity toward
phosphorylation at Ser422 (Yoshida et al., 2004) thus regulating
hydrolysis at Asp421 by caspase-3. In fact, phosphorylation
at Ser422 has shown to protect against caspase hydrolysis
at Asp421 (Guillozet-Bongaarts et al., 2005, 2006; Kolarova
et al., 2012). In physiological conditions Tau is responsible
not only for the stabilization of neuronal cytoskeleton
by its binding to tubulin monomers but also for many
intra and extracellular signaling processes (Kolarova et al.,
2012).
NOVEL COMPOUNDS TARGETING JNK
INHIBITION
Inhibition of JNKs is an attractive therapeutic strategy that has
been investigated with considerable recent eﬀort from both the
pharmaceutical industry and academia. The development of JNK
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inhibitors prior to 2010 has been extensively reviewed by Siddiqui
and Reddy (2010). A recent review of patents claiming inhibitors
of all JNK isoforms published between 2010 and 2014 can be
consulted (Gehringer et al., 2015).
Within the past years, few small molecule inhibitors of JNKs
have entered clinical trials for diﬀerent indications, but none for
the treatment of AD. Current compounds under evaluation are:
bentamapimod for the treatment of inﬂammatory endometriosis,
CC-930 (tanzisertib) for the treatment of idiopathic pulmonary
ﬁbrosis and discoid lupus erythematous as well as D-JNKi1
for the treatment of inﬂammation and stroke (as reviewed by
Koch et al., 2015). In the following sections, and represented
in Tables 1 and 2 and Figure 3, current knowledge of the JNK
inhibitors will be described (Bogoyevitch et al., 2004; Wang
et al., 2004; Bogoyevitch and Arthur, 2008; Antoniou et al.,
2011).
Direct ATP-Competitive Inhibitors:
SP600125
Since the ﬁrst JNK inhibitors were synthesized, the use
of SP600125 (Anthra[1,9-cd]pyrazol-6-(2H)-one; Bogoyevitch
et al., 2004) has been increasingly used in order to understand
and elucidate the role of JNK in pathological conditions and
a purported therapeutic role of SP600125 (i.e., Zhou et al.,
2015). However, it is to note that SP600125 has shown
a limited speciﬁcity toward JNK, as also inhibits not only
MKK4 and MKK7, but also other protein kinases unrelated
to JNK, such as SGK, p70 ribosomal protein S6 kinase
(S6K1), AMPK, CDK2, CK1d, and DYRK1A (Bain et al.,
2003).
In both in vitro and in vivo models of AD, SP600125 has
demonstrated to prevent the pathological mechanisms triggered
by the up-regulation of pJNK (Table 1). In vitro, SP600125
has demonstrated that this inhibitor prevents βAPP induced
neuronal cell death as well as down-regulation of ASK1 in F11
cell-lines (Hashimoto et al., 2003). Interestingly, the study did
not ﬁnd neuroprotection against βAPP induced neuroapoptosis
when exposing cultures to a p38 inhibitor, which highlights
the importance of JNK within this process. Other in vitro
experiments showed decrease of Aβ-induced cytokine expression
(IL6, IL8, MIP1β, TNFα, Groα, GM-CSF; Bamji-Mirza et al.,
2014). In vivo studies have shown that intracerebroventricular
administration of SP600125 improved escape latency in the
Morris WaterMaze (Ramin et al., 2011). In AD transgenic mouse
model (APPxPS1), administration of SP600125 improved spatial
learning impairment in the Morris Water Maze, and reduced
pTau and Aβ oligomeric burden (Zhou et al., 2015).
TABLE 1 | Use of SP600125 as a possible therapeutic target in Alzheimer’s disease.
Experimental model Findings Reference
In vitro F11 cells Blockade of βAPP dimerization and ASK1 (MAP3K5) mediated
neuronal cell death
Hashimoto et al., 2003
Hippocampal cell culture from Wistar rats Increased synaptic transmission in CA1 region Costello and Herron, 2004
Murine L929 fibroblasts Block of τ phosphorylation induced by WOX1 knock-down in cell
culture
Sze et al., 2004
Primary rat microglia culture Reduced nitrite accumulation and prevention of iNOS’s activation in
glial cells
Bodles and Barger, 2005
Primary cortical cell culture from Sprague Dawley
rat
Inhibition of Bcl-w and Bcl-xL down-regulation Yao et al., 2005
Neuroglioma U251 cells Inhibition of IL1β induced sAPPα release Ma et al., 2005
PC12 cells Attenuation of 4-hydroxynonenal induced apoptosis Cho et al., 2009
Cultured human brain endothelial cells Inhibition of Aβ induced AP-1 activation and MCP1 Vukic et al., 2009
Primary rat hippocampal culture Inhibition of both hetero- and autophosphorylation of JNK Vogel et al., 2009
Human neuroglioma H4 cells expressing Swedish
APP695 or intracellular APP C99
Inhibition of staurosporine-induced Aβ Chae et al., 2010
SK-N-SH cell line Reduction of passive calcium leak in endoplasmic reticulum Das et al., 2012
Primary cortical cell culture from Sprague Dawley
rat
Reduction of morphine induced τ phosphorylation Cao et al., 2013
CMEC/D3 cells Reduction of Aβ induced cytokine expression Bamji-Mirza et al., 2014
Primary glial culture from Swiss-Webster mice Increase of ApoE/ABCA1 expression Pocivavsek and Rebeck, 2009
In vivo Male Swiss-Webster mice Increase of ApoE/ABCA1 expression Pocivavsek and Rebeck, 2009
Male albino Wistar rats Improvement of escape latency on Morris Water Maze Ramin et al., 2011
Drosophila sp. fly strains Rescue of Aβ42 induced apoptosis Hong et al., 2012
Male C57BL/6 mice Reduction of PS1 expression Rahman et al., 2012
Sprague Dawley neonatal rats Attenuate isoflurane-induced hippocampal apoptosis mediated by
JNK
Li et al., 2013
APPswe/PS1dE9 mice Reversion of synaptic loss, decrease of IL1β, IL6 and TNFα
expression, decrease of phosphorylated τ, increase of αAPP,
decrease of βAPP and Aβ oligomers and improvement of spatial
learning
Zhou et al., 2015
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FIGURE 3 | Pharmacology of JNK inhibitors, targets and mechanism of action. CPPi, cell-permeable peptide inhibitors; ATP-c, direct ATP-competitive
inhibitors; MLKi, mixed linage kinase inhibitors.
Mixed Linage Kinase Inhibitors
As already mentioned, MLKs have been thought to be a
plausible target. Their inhibition could lead to down-regulation
of the JNK signaling pathway resulting in antiapopototic and
neuroprotective outcomes within neuropathological models. As
a result of this, diﬀerent MLK inhibitors have been developed in
order to assess their potential role as a possible therapeutic agent
in diﬀerent pathologies, such as AD (Table 2) or Pick’s disease.
The indolocarbazole K252a was the ﬁrst MLK inhibitor
found in Nocadiopsis sp. and it has been frequently used in
experimental models implicating JNK signaling. In cell culture
studies, it has been shown that K252a conferred neuroprotection
to Aβ-exposed hippocampal cells (Goodman and Mattson, 1994)
and prevented Aβ-induced neuroapoptosis (Xu et al., 2009)
which could be of potential beneﬁt in AD. The compound
CEP1347 derives from K252a by addition of two ethylthiomethyl
groups (Saporito et al., 2002) and acts over MLK1,MLK2, MLK3,
DLK (dual leucine zipper kinase) and LZK (Leucine zipper-
bearing kinase; Bogoyevitch et al., 2004). CEP1347 reached
clinical phase studies (Parkinson Study Group, 2004; Parkinson
Study Group PRECEPT Investigators, 2007; Schwid et al., 2010)
for the treatment of Parkinson’s disease (PD; Wang et al., 2004).
Unfortunately, the results were disappointing. Regarding AD,
CEP1347 has been shown to prevent Aβ-induced neuronal cell
death and it reduced caspase-3 activity (Bozyczko-Coyne et al.,
2001; Troy et al., 2001).
CEP11004 is another carbazole-derived MLK inhibitor
that has proved to be useful in PD models, as this compound
prevented 6-hydroxydopamine-induced neuroapoptosis in
neurons of the substantia nigra (Ganguly et al., 2004) and
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TABLE 2 | Use of different JNK inhibitors as a possible therapeutic target in Alzheimer’s disease.
JNK Inhibitor Experimental Model Findings Reference
Mixed linage kinase inhibitors
K252a Primary cell culture Conferred neuroprotection to Aβ-exposition Goodman and Mattson, 1994
Primary cell culture Prevention against Aβ-induced neuroapoptosis Xu et al., 2009
CEP1347 Primary cell culture Prevention against Aβ-induced neuronal cell Bozyczko-Coyne et al., 2001
PC12 cell cultures Prevention against Aβ-induced neuronal cell death Troy et al., 2001
Peptide inhibitors
TAT-TIJIP Primary cell culture Prevention against neuronal apoptosis Meade et al., 2010
Primary cell culture Decrease of neuronal degeneration and dendrite loss Meloni et al., 2014
D-JNKi1 TgCRND8 mice Decrease of APP phosphorylation. Improvement of
memory
Sclip et al., 2011
3xTg-AD mice with traumatic brain injury Prevention of Tau phosphorylation Tran et al., 2012
TgCRND8 mice Decrease of synaptic loss and preventing synaptic
dysfunction
Sclip et al., 2014
C57BL/6J mice + corticosterone regimen Decrease of pTau levels and neuronal cell death Solas et al., 2013b
Natural inhibitors
ω-fatty acids Tg2576 mice on DHA regimen Decreased PI3K activity. Increase of caspase-cleaved
actin
Calon et al., 2004
C57BL/6J mice on DHA regimen Decrease of both γ and β-secretase activity Grimm et al., 2011
Tg2576 mice on DHA regimen Decrease of Aβ levels Lim et al., 2005
Neuronal cell culture Prevented IRS-1 inactivation and pTau pathology Ma et al., 2009
Curcumin 3xTg-AD mice Reduced Aβ, plaque deposition, and cytoquines levels Ma et al., 2009
APPswe/PS1dE9 mice Reduced hippocampal Aβ40/42 levels Feng et al., 2014
APPswe/PS1dE9 mice Spatial learning and memory improvements. Reduced
hippocampal Aβ levels
Wang et al., 2014
Tg2576 mice Reduced amyloid levels and plaque burden. Direct
Aβ-binding prevention of fibril formation and
aggregation
Yang et al., 2005
DHA, Docosahexaenoic acid; PI3K, phosphoinositol 3 kinase.
it also appeared as a good inhibitor of the JNK cascade in a
MPTP-induced cellular stress model (De Girolamo and Billett,
2006). Further studies will be needed to evaluate the eﬀects of
CEP11004 in AD experimental models for its possible relation
with the AD-related pathological mechanisms explained above.
URMC099 is a novel MLK inhibitor with good blood-brain-
barrier-penetrating properties which has already been shown to
be useful in reducing inﬂammatory response both in vivo and
in vitro models (Goodfellow et al., 2013; Marker et al., 2013).
However, no studies have been performed up to date to evaluate
the eﬀects of URMC099 in neurodegenerative models.
In summary, although the use of MLK inhibitors has been
limited in the AD ﬁeld, further studies are expected to come.
Cell-Permeable Peptide Inhibitors
Peptide inhibitors of JNK are peptide sequences that speciﬁcally
bind to the JNK binding domain (JBD) leading to its inhibition
(Bogoyevitch et al., 2004; Borsello and Bonny, 2004). Their
characterization came primarily from studies that conﬁrm the
interaction of highly expressed JIP1 with JNK, showing that
high concentrations of JIP1 are able to induce inhibition of JNK
and down-regulation of JNK substrates (Dickens et al., 1997).
A conserved 21 aminoacid long sequence was ﬁrstly identiﬁed
within JNK’s primary protein conformation at position 143–163
(Barr et al., 2002; Bogoyevitch et al., 2004). This region is widely
known to be the JBD where JIP1 mediates down-modulation
over JNK, leading to its inhibition. Puriﬁcation of the 143–163
region and synthesis of the polypeptide out of this sequence,
named I-JIP, showed the capacity of triggering inhibition of JNK.
Moreover, a shorter polypeptide obtained from the sequence
speciﬁed in-between 153 and 163 demonstrated to exert the
minimal inhibitory eﬀect on JNK. This compound receives the
name of TI-JIP (Barr et al., 2002; Bogoyevitch and Arthur,
2008).
However, the disadvantages that result from the relative non-
permeability of JIP need to be solved. Cell-penetrating peptides
(CPPs) are small peptides (typically 5–25 amino acids), which
are used to facilitate the delivery of normally non-permeable
cargos such as other peptides, proteins, nucleic acids, or drugs
into cells (Meloni et al., 2014). Hence the observation of Borsello
et al. (2003) of attaching permeabilizer-compounds to JIP, such
as TAT 48–57 or antannapedia, with the objective of facilitating
the diﬀusion of peptides through membranes in order to exert
their action over the desired targets. In this way, diﬀerent
post-modiﬁcations were performed that led to the synthesis of
the JNK inhibitors JNKi. Furthermore, the in vitro synthesis
of these compounds using pure D-isomers with the intention
of preserving protein functionality and avoiding proteolytic
instability, led to obtaining of D-JNKi1 and its L-isomer
(L-JNKi1; Borsello and Bonny, 2004). A peptide inhibitor of c-Jun
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has also been synthesized, the Tat-c-Jun peptide (Holzberg et al.,
2003; Antoniou et al., 2011). In this scenario, peptide inhibitors
show themselves as promising molecules for targeting JNK, as
these compounds have the advantage of speciﬁcity toward other
kinases (Barr et al., 2002). In fact, one of the most important
disadvantages shown by other synthetic JNK inhibitors, such as
SP600125 or MLK inhibitor, is their lack of speciﬁcity toward
their target (Bogoyevitch et al., 2004).
JNK-interacting protein derived compounds have been
studied for their possible role in preventing neurodegenerative
pathways in which JNK has been shown to be implicated. TAT-
TIJIP (Tat cell transporter sequence-bound truncated form of
I-JIP) has been demonstrated to be able to prevent neuronal
apoptosis via JNK inhibition. TAT-TIJIP eﬀectively prevented
cell death by interfering with several processes which have been
identiﬁed as leading to cell death by necrosis. In particular,
reactive oxygen species production was reduced and the
increase in cytosolic calcium following the excitotoxic insult
was attenuated. These neuroprotective properties of JNK peptide
inhibitors likely reﬂect their abilities to prevent cell death by
necrosis as well as apoptosis (Arthur et al., 2007). In diﬀerent
studies the neuroprotective eﬃcacy of four CPPs, namely TAT,
penetratin, Arg-9, Pep-1 was shown in a glutamic acid, kainic
acid and in vitro ischemia injury model (Meloni et al., 2014).
AP-1 inhibitory peptides (both full-length and truncated) have
also shown neuroprotective eﬃcacy in kainic acid and glutamate
neuronal excitotoxicity models (Meade et al., 2010). However,
it is to note that TAT-like peptides and other non-related CPPs
possess intrinsic neuroprotective properties (Meloni et al., 2014)
and pose the question of the contribution of the CPP versus cargo
in the neuroprotective eﬀect.
D-JNKi1 is the most frequently used inhibitor in experimental
neurodegenerative models. It has been shown useful to reverse
ischemia-induced neuronal damage (Borsello et al., 2003). It has
been demonstrated that D-JNKi1 is able to decrease levels of
APP in human neuroglioma H4 cell lines with the consequent
reduction of the βAPP levels and Aβ burdens, and it also
shifted APP processing toward the non-amyloidogenic pathways,
promoting this non-amyloidogenic processing (Colombo et al.,
2009). Again, these events are of high interest as they are directly
related to the central pathogenesis of AD.
Regarding AD models (Table 2), diﬀerent studies have
conﬁrmed the potential therapeutic beneﬁt of inhibitors for their
capacity to interact within a wide variety of molecular signaling
processes implicated in this pathology. Sclip et al. (2011) pointed
out the eﬃcacy of D-JNKi1 in the mice-based AD model
TgCRND8, in which it demonstrated to prevent JNK action
leading to rescue memory impairments (behavioral studies) as
well as the LTP deﬁcits of TgCRND8 mice. Moreover, D-JNKI1
inhibited APP phosphorylation in Thr-668 and reduced the
amyloidogenic cleavage of APP and Aβ oligomers (Sclip et al.,
2011). Tran et al. (2012) demonstrated that D-JNKi1 mediated
down-regulation of JNK prevented Tau phosphorylation in an
AD transgenic model (PS1xAPPxTau). D-JNKi1 has also proved
beneﬁcial in another transgenic mice model of AD (TgCRND8),
by rescuing synaptic loss and potentiating LTP (Sclip et al., 2014).
The increase in pTau levels and neuronal cell death shown in
a stress model of AD was also reversed by administration of
D-JNKi1 (Solas et al., 2013a). In this scenario, peptide inhibitors
could represent a good therapeutic option for the continuously
widening therapeutic armamentarium in AD.
Natural Inhibitors
Three diﬀerent compounds can be mentioned in this section:
latifolians, ω-fatty acids (ω-FAs) and curcumin. Latifolians A
and B are natural compounds isolated from the stem bark
of the Papua New Guinean vine Gnetum latifolium that have
been identiﬁed as inhibitors of JNK3 (Rochfort et al., 2005).
However, no studies have been performed assessing the possible
use of latifolians as neuroprotective agents in neurodegenerative
models.
On the other hand, the identiﬁcation of ω-FAs as JNK
inhibitors (Ma et al., 2009) could represent a new therapeutic
opportunity in AD. The implication of PUFAs (polyunsaturated
fatty acids) in neurodegenerative diseases is currently widely
accepted. Changes in the lipid-metabolism as a source for
reactive oxygen species production and the implication of a
dys-homeostasis within the regulation of cholesterol-derivates
have been described to play an important role in the
development of AD (Corsinovi et al., 2011). In fact, an adequate
ω-FAs/cholesterol ratio plays an important role in the regulation
of APP-processing pathway, and it has also been suggested
that a low consumption of ω-FAs could lead to a major up-
regulation of proinﬂammatory responses (Corsinovi et al., 2011).
The administration of ω-FAs prevented IRS-1 (insulin receptor
substrate-1) inactivation and pTau pathology by inhibition
of the JNK signaling in in vitro (neuronal cultures from
embryonic Sprague Dawley rats), in vivo models (3xTransgenic
ADmice) and post-mortem humanAD samples (Ma et al., 2009).
Altogether it suggests the importance of further studies which
could conﬁrm the beneﬁcial outcomes of the use of ω-FAs in the
histopathological processing of AD.
Curcumin is a natural compound which resides in the
Zingiberaceae sp. family. Aside from its implications as an
anti-inﬂammatory and antioxidant agent, curcumin has also
demonstrated to play a direct role in the modulation of the JNK
pathway (Chen and Tan, 1998). As a result, diﬀerent studies have
proposed an underlying role of curcumin toward the inhibition of
JNK, demonstrating its capacity to ameliorate MPTP (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) and MPP+ (1-methyl-4-
phenylpyridnium) induced neuronal loss models both in vivo
and in vitro (Yu et al., 2010). It also promotes an increase in
the expression of HSPs (heat shock proteins) that are centrally
implicated in preserving the functionality of the proteasome-
mediated degradation of abnormally misfolded proteins (Maiti
et al., 2014).
Regarding AD models (Table 2), curcumin showed a
signiﬁcant reduction in Aβ40 and Aβ42 levels within the
hippocampal structures in APPswe/PS1 mouse after 6-months
follow up (Feng et al., 2014) as well as a reduction in Aβ
levels and senile plaques histopathology in Tg2576 mice model
(Yang et al., 2005). In addition to this, it also demonstrated
a signiﬁcant improvement of the spatial learning and memory
ability after a 3-months dosage regimen, as well as a reduced
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expression of presenilin 2, and an increased activity of Aβ
degrading enzymes such as neprilysin (Wang et al., 2014). In
fact, combination of docosahexanoic acid (ω-3 FA) and curcumin
showed reduced phosphorylation of JNK and tau as well as a
decreased degradation of IRS1 in 3xTg AD mice, leading to
an Y-maze performance improvement due to a possible role
of curcumin in an insulin-sensitization process which directly
supports and preserves the insulin tropism within cerebral tissue
(Ma et al., 2009). In this way, curcumin could be considered an
encouraging proposition as a therapeutic potential drug in AD.
CONCLUSION
The JNK cascade is nowadays understood as an axis in the
molecular development of AD and other neurodegenerative
pathologies. Its implication at diﬀerent stages of the disease
makes clear its importance within neuronal dysregulation,
metabolic disruption as well as in formation of pathological
structures. Nowadays, diﬀerent pharmacological agents are
available for experimental and preclinical use assessing the
possible role of JNK as a plausible therapeutic target in AD.
Signiﬁcant progress in the design of selective JNK inhibitors
versus other kinases has been achieved within the past years.
However, directed inhibition of JNK isoforms in speciﬁc tissues
is still an open task. Newer compounds are being developed with
increased speciﬁcity toward JNK inhibition (Uitdehaag et al.,
2012). The fact that JNK3 is speciﬁcally expressed in the CNS
and its activation by stress-stimuli renders it an attractive and
potential target for treating AD. It is possible to speculate that
JNK3 speciﬁc inhibition will reduce the possible side-eﬀects of
a systemic JNK inhibition. Although there is no consensus in
literature whether isoform selectivity is needed for the treatment
of AD, the answer to this question can only be obtained when
such compounds are available.
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